P3. 13-15 First-Line Afatinib Dose Initiation and Adjustment in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer
Background: The recommended starting dose of afatinib is 40mg od with 20mg, 30mg and 50mg tablets available for dose adjustment. Method: This is a retrospective observational study of starting dose, dose adjustment and optimal dose of first-line afatinib in patients withEGFR mutant advanced non...
Saved in:
Main Authors: | Chai, Chee Shee, Liam, Chong Kin, Ho, G., A., Binti Alip, Pang, Y. |
---|---|
Format: | E-Article |
Language: | English |
Published: |
Elsevier
2018
|
Subjects: | |
Online Access: | http://ir.unimas.my/id/eprint/22821/1/JTO%20dose.pdf http://ir.unimas.my/id/eprint/22821/ https://www.jto.org/ |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma
by: Chai, Chee Shee, et al.
Published: (2019) -
P3. 15-21 Real-World Experience of First-Line Afatinib Treatment in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer.
by: Chai, Chee Shee, et al.
Published: (2018) -
Comparison of pattern of disease progression and prevalence of acquired T790M mutation in Malaysia patients with EGFR mutant lung adenocarcinoma upon failure of first-line afatinib, gefitinib and erlotinib
by: Chai, Chee Shee, et al.
Published: (2019) -
Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study
by: Chai, Chee Shee, et al.
Published: (2019) -
Epithelial-to-mesenchymal transition (EMT) causing acquired resistance to afatinib in a patient with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma
by: Chai, Chee Shee, et al.
Published: (2018)